Celldex Therapeutics, Inc. CLDX
31.10
(0.38)
(1.21%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow CLDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
3,265.42 | 1,353.51 | 663.24 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(50.45) | (32.19) | (28.21) | — | |
P/B ratio |
4.05 | 4.63 | 3.42 | — | |
Price to Tangible BV |
4.21 | 4.92 | 3.61 | — | |
EV/Sales |
2,459.27 | 1,065.73 | 473.52 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(9.26) | (7.48) | (6.11) | — | |
EV/FCF |
(9.01) | (7.35) | (6.03) | — | |
Quick Ratio |
11.71 | 8.78 | 10.21 | 12.55 | |
Current Ratio |
11.82 | 8.92 | 10.49 | 13.01 | |
Net Debt/EBITDA |
8.80 | 5.36 | 5.93 | 7.90 | |
Debt/Assets |
0.16% | 0.00% | 0.21% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 0.83 | 0.79 | 0.73 | |
Capex/Depreciation |
3.99 | (7.32) | 19.41 | 2.27 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
307,009.09% | 486,673.33% | 62,777.50% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
59,559.09% | 76,326.67% | 9,950.83% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.05 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
38,218.18% | 56,820.00% | 7,424.17% | 0.00% | |
Graham Net Nets |
0.23 | 0.19 | 0.27 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(11.69%) | (13.43%) | (14.32%) | — | |
Free Cash Flow Yield |
(8.36%) | (10.72%) | (11.84%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.74) | (0.99) | (0.96) | (0.73) | |
Capex per Share |
(0.04) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.78) | (1.01) | (0.98) | (0.74) | |
Cash per Share |
9.22 | 6.78 | 7.81 | 8.78 | |
Shareholders Equity per Share |
9.18 | 6.85 | 7.94 | 9.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.18 | 6.85 | 7.94 | 9.01 | |
Free Cash Flow |
(60.59) | (67.23) | (65.22) | (49.07) | |
Working Capital |
663.61 | 407.75 | 483.67 | 557.87 | |
Capital Expenditures |
(3.18) | (1.64) | (1.28) | (0.44) | |
Net Current Asset Value |
657.15 | 404.19 | 478.85 | 554.26 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
144.50 | 109.27 | 10.68 | 0.00 | |
Net Profit Margin |
(334,104.55%) | (524,566.67%) | (67,764.17%) | 0.00% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.16 | 0.65 | 1.36 | 0.47 | |
Average Payables |
8.37 | 6.88 | 2.22 | 2.69 | |
Average Assets |
737.38 | 625.36 | 687.66 | 735.81 | |
Average Common Equity |
684.99 | 579.60 | 637.08 | 692.13 |
Columns are period end dates